D
David A. Cooper
Researcher at Pfizer
Publications - 965
Citations - 81765
David A. Cooper is an academic researcher from Pfizer. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Viral load. The author has an hindex of 117, co-authored 903 publications receiving 69249 citations. Previous affiliations of David A. Cooper include Boston Children's Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Cd8+ lymphocyte responses to antiretroviral therapy of HIV infection
TL;DR: The CD8+ lymphocyte proliferation observed with protease inhibitor therapy could result in improved suppression of HIV replication by the immune system and should be confirmed in a prospective trial comparing protease inhibitors with both nucleoside and non-nucleoside analog therapies.
Journal Article
Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection.
Philippe Vanhems,Clément Dassa,Jean Lambert,David A. Cooper,Luc Perrin,Jeanette Vizzard,Bernard Hirschel,S. Kinloch-de Loes,Andrew Carr,Robert Allard +9 more
TL;DR: A classification and data reduction of clinical features among 218 patients with acute HIV-1 infection enrolled in four prospective seroincidence studies were assessed, finding grouping of symptoms and signs based on groups of patients is potentially more informative than observations made on individual patients.
Journal ArticleDOI
Scytalidium dimidiatum and Lecythophora hoffmannii: unusual causes of fungal infections in a patient with AIDS.
TL;DR: A human immunodeficiency virus-infected patient is described who had simultaneous infections with two fungi which are rare causes of serious infection: Lecythophora hoffmannii and Scytalidium dimidiatum, causing skin lesions, lymphangitis, and lymphadenitis.
Journal ArticleDOI
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study
Laura Dickinson,Janaki Amin,Laura Else,Marta Boffito,Deirdre Egan,Andrew Owen,Saye Khoo,David Back,Catherine Orrell,Amanda Clarke,Marcelo H. Losso,Praphan Phanuphak,Dianne Carey,David A. Cooper,Sean Emery,Rebekah Puls +15 more
TL;DR: A higher rate of EFV-related adverse events and discontinuations due to these events for EFV600 were not driven by polymorphisms assessed, and implementation of EFv400 would improve toxicity management whilst still maintaining good efficacy.
Journal ArticleDOI
Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.
Peter Cardiello,Rolf P. G. van Heeswijk,Elly A. M. Hassink,Preeyaporn Srasuebkul,Apicha Mahanontharit,Tarika Samor,Wassana Worarien,Jos H. Beijnen,Richard M. W. Hoetelmans,Kiat Ruxrungtham,David A. Cooper,Joep M. A. Lange,Praphan Phanuphak +12 more
TL;DR: Clinical and pharmacokinetic data support once‐daily SQV‐SGC/RTV (1600/100 mg) with two NRTIs as a convenient and safe therapeutic regimen to maintain viral suppression and immune function in HIV‐1‐infected patients with plasma viral loads of <50 copies/mL.